Ibex Medical Analytics vs Mindpeak
Two computational pathology companies doing different work on the same slide. Ibex detects cancer, with prostate, breast and gastric solutions in routine clinical use, United States clearance as an in vitro diagnostic for the prostate product, peer reviewed publication behind it and the most complete published certification set of any vendor in this index. Mindpeak quantifies biomarkers rather than finding tumours, with eleven European marked algorithms covering breast markers and lung immunotherapy scoring, distributed both directly and embedded inside a partner platform. A laboratory looking to catch what a pathologist might miss on a prostate biopsy is buying Ibex. One trying to make its immunohistochemistry scoring reproducible across pathologists is buying Mindpeak. The regimes differ too, so check that the product you want is usable for diagnosis in your market, not just available in it.
- The certification set is the most complete of any vendor in this index, and the deployment evidence is verifiable through third parties rather than resting on vendor claims.
- The cleared indication is one of the most conservative and best constructed here, which is the right posture for software that flags cancer on a slide a pathologist will sign.
- Three cancer types are in routine clinical use worldwide, covering prostate, breast and gastric, with peer reviewed publication behind the deployment scale.
- Eleven marked algorithms across the highest volume biomarker workload in European pathology, covering breast markers and lung immunotherapy scoring rather than cancer detection alone.
- Genuinely independent published evidence exists, which is rarer in this lane than it should be, and the technical claim about its breast immunohistochemistry model is specific and checkable.
- Reach comes through platform distribution as well as direct sale, so a laboratory already running a partner platform can adopt the algorithms without a separate integration project.
Side by Side
| Axis | I Ibex Medical Analytics |
M Mindpeak |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
The regulatory regimes differ and are not interchangeable: one holds United States clearance as an in vitro diagnostic, the other holds a European marked portfolio, and a product available for clinical use in one market may not be usable for diagnosis in the other.
Mindpeak publishes no information security management certification and no health privacy position; Ibex publishes no explicit business associate commitment though its certification set is closely aligned with the privacy requirements. Neither publishes pricing. Neither publishes a bias evaluation, and staining and scanner variation between laboratories remains the largest uncontrolled variable in both products.